[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651060":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":38,"locations":46,"responsibleParty":70,"collaborators":11,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":11,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Alkermes, Inc.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Level 1","EXPERIMENTAL",null,[13],"Drug: ALKS 7290",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose Level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Dose Level 3",[13],{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo","PLACEBO_COMPARATOR","Placebo capsule taken daily",[25],"Drug: Placebo",[27,32],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","ALKS 7290","ALKS 7290 tablets taken daily, orally, for 4 weeks",[9,15,18],{"type":28,"name":21,"description":23,"armGroupLabels":33,"otherNames":11},[21],[35],{"name":36,"affiliation":5,"role":37},"Medical Director, MD","STUDY_DIRECTOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Global Clinical Services","CONTACT","888-235-8008 (US Only)","clinicaltrials@alkermes.com",{"name":40,"role":41,"phone":45,"phoneExt":11,"email":43},"571-599-2702 (Global)",[47,61],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":11},"Alkermes Investigator Site","RECRUITING","Chino","California","91710","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-117.68894,34.01223,{"lat":59,"lon":58},{"facility":48,"status":49,"city":62,"state":63,"zip":64,"country":53,"countryCode":54,"cosmosGeoPoint":65,"geoPoint":69,"contacts":11},"Maitland","Florida","32751",{"type":56,"coordinates":66},[67,68],-81.36312,28.62778,{"lat":68,"lon":67},{"type":71,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100651060","a-study-to-evaluate-safety-and-efficacy-of-alks-7290-compared-with-placebo-in-adult-participants-with-attention-deficit-hyperactivity-disorder-alks-7290-201-100651060",false,"NCT07755410","A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)","A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder","Inclusion Criteria:\n\n* Meets the Diagnostic and Statistical Manual of Mental Disorders -5 criteria for ADHD, as confirmed by the Mini-International Neuropsychiatric Interview (MINI) for ADHD Studies 7.0.2.\n* Is otherwise healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring. Participants must be stable on permitted medication for 2 months prior to first visit, without anticipated changes to dose.\n* AISRS total score of ≥26\n* CGI-S score ≥ 4 (moderately ill or worse)\n* Has a Body Mass Index within 18 to 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Has a known history of intellectual developmental disorder or cognitive impairment that, in the opinion of the Investigator, would interfere with study participation.\n* Has any of the following psychiatric conditions per the DSM-5 criteria, as assessed by the MINI. Conditions not assessable by the MINI should be assessed by clinical judgement; Diagnosis of schizophrenia, schizoaffective disorder, or bipolar I or II disorder, or current, unstable, MDD or GAD.\n* Clinically significant cognitive difficulties including dementia, delirium or amnestic syndromes, or any other cognitive disorder present with the past 2 years that could interfere with participation in the study.\n* Moderate to severe substance use disorder according to DSM-5 guidelines, including use of alcohol, nicotine, cannabis, narcotics, or any illicit substance.\n* Any other psychiatric condition that could interfere with participation in the study.","ALL","18 Years","65 Years",{"count":83,"type":84},312,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.",[90],"Attention Deficit Disorder With Hyperactivity (ADHD)",[92,93],"ADHD","Attention Deficit Disorder with Hyperactivity","2026-08-05",{"date":96,"type":97},"2026-08-10","ACTUAL",{"date":99,"type":84},"2026-08",{"date":101,"type":84},"2027-07",{"name":5,"class":6},2]